The annual cost of asthma and chronic obstructive pulmonary disease (COPD) for the NHS is estimated as £3 billion and £1.9 billion respectively. In total, all lung conditions (including lung cancer) directly cost the NHS in the UK £11 billion annually.

Respiratory diseases can be a major factor in winter pressures faced by the NHS; most admissions are non-elective and during the winter period these double in number. Switching to deliver respiratory care in the community can help reduce this pressure on the NHS.

Our Respiratory Therapy – Equipment and Consumables Framework Agreement covers the treatment of sleep apnoea, provision of non-invasive ventilation and assists patients with mucus clearance. All the goods and services provided support the diagnosis and ongoing treatment of the patient throughout their therapy care pathway from the trust’s premises to the patients’ home, supporting the NHSE 2024/25 priorities and operational planning guidance of implementing virtual wards. The framework agreement also includes the long-term observations and compliance reporting of the patient.

There is a home delivery service that ensures patients receive their necessary respiratory therapy consumables directly at home, enhancing convenience and compliance with treatment plans. This service helps maintain continuity of care and improves patient outcomes.

The products and services provided help patients self-manage their respiratory disease, which can help prevent unnecessary hospital admissions.”

If this framework agreement doesn’t cover the goods or services you require, or a framework agreement isn’t the optimal route to market for your needs, we can provide tailored strategic procurement support. Find out more here.